Drug intelligence / Profile preview

MucoTabS

Development stage: Preclinical
Lead developer: SkyePharma
Modality: Small Molecules
Administration: Oral

Overview

MucoTabS is a preclinical-stage, site-specific extended-release oral tablet formulation developed through a collaboration between Chiron Corporation and SkyePharma. The technology is designed to achieve targeted drug release within the gastrointestinal tract, utilizing proprietary delivery mechanisms to optimize the pharmacokinetic profile of active pharmaceutical ingredients. By controlling the site and rate of release, MucoTabS aims to improve the bioavailability and therapeutic efficacy of drugs that may otherwise have narrow absorption windows or require localized action. As of 2024, the program remains in the preclinical phase of development within SkyePharma's innovation pipeline.

Brand names: MucoTabS
Other names: MucoTabS

Beyond the preview

Go deeper on MucoTabS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MucoTabS.

Explore the full profile